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The cure rate of patients with testicular cancer is excellent,
approaching 100% for the early stages. For these stages of
the disease, research is now directed at developing treatment
schedules with minimum toxicity, by reducing the size of
radiotherapy fields, decreasing doses of chemotherapy and
radiotherapy, or by the application of a surveillance policy.
Such minimal therapeutic regimens need frequent and
specialized follow-up at cancer centres. Knowledge of the
total number of cases and the stage distribution of the
patients will have an impact on the planning of follow-up
schedules and resource allocation. The present study
examines changes in these parameters at our centre during
the last 18 years.
Patients and methods
From the National Cancer Registry all adults (15 years or
older) who were living in the south-eastern counties of Nor-
way at the time of their diagnosis of cancer of the testis
during the years 1970 to 1987 were identified. These 777
patients were matched with the registry of patients referred
to the Norwegian Radium Hospital (NRH) for primary
treatment of testicular cancer during the same period.
Twenty-five patients were excluded from the final analysis
mainly because review of the histological specimens showed
non-germ cell histology. The remaining 752 patients represent
96% of the cases reported to the Cancer Registry by July
1988. These patients have all undergone primary staging and
treatment at the NRH. We reviewed their medical records,
noting the year of orchiectomy, age, histological classification
(seminoma/non-seminoma), and stage of disease at presenta-
tion. Stage was defined according to the Royal Marsden
classification (Peckham et al., 1979) after clinical and
radiological examinations, not taking into account the results
of surgical procedures. Until 1980, all patients had lympho-
graphy; all seminomas had this investigation until 1984.
Computed tomography (CT) of the abdomen was introduced
in the routine diagnostic work-up of the non-seminoma
patients around 1978, chest CT starting only gradually in the
early 1980s.
The material was analysed for changes of stage distribu-
tion, represented as the proportion of patients presenting in
stage 1, using x2 tests during three periods (1970-75,
1976-81, 1982-87). A value for P <0.05 was noted as
significant.
Results
The total number of cases increased from 187 to 326 (74%)
from the first to the last three-year period (Table I). The rise
has affected both histological subgroups equally: seminomas
rising from 88 to 154 (75%), non-seminomas from 99 to 172
(74%). The percentage distribution by histology was
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unchanged over the period studied with seminoma 47% and
non-seminoma 53%.
For the whole series there was a statistically significant
increase in stage 1 (Table I); this is mainly owing to a large
increase in stage 1 seminoma (Table II). In the non-
seminomas, the increase in total number of cases is fairly
evenly distributed over the stages (Table III).
The mean age at diagnosis was 40.3 years (95% confidence
interval 39.1-41.6) for seminoma patients and 29.8 years
(95% confidence interval 28.8-30.8) for non-seminoma
patients. The mean age in seminoma patients changed from
43.3 years (95% confidence interval 40.7-45.9) during the
first period to 39.3 years (95% confidence interval 37.2-41.4)
during the second and 39.3 years (95% confidence interval
37.4-41.2) during the last period. There was no correspond-
ing change in mean age for the non-seminoma patients.
The increase in cases treated during 1970-87 was 74%.
The number of males aged 15 to 66 years living in the
south-eastern counties increased by 19% between 1971 and
1987 (Norwegian Population Registry, personal communica-
tion). A small proportion of the rise in the number of cases
can, therefore, be accounted for by an increase in the popula-
tion at risk. There has been no major change in referral
patterns during the periods studied. Most of the increase in
the number of cases treated, therefore, is due to a large
increase in the incidence of testicular carcinoma in the south-
eastern counties of Norway. This was confirmed when cal-
Table I Distribution of testicular cancer NRH 1970-87: all
cases
1970-75 1976-81 1982-87 Total
Stage No. % No. % No. % No. %
1 101 54.0 148 61.9 218 66.9 467 62.1
2 to 4 86 46.0 91 38.1 108 33.1 285 37.9
Total 187 100 239 100 326 100 752 100
P = 0.015; x2= 8.355; DF = 2.
Table II Distribution of testicular cancer NRH 1970-87:
seminoma
1970-75 1976-81 1982-87 Total
Stage No. % No. % No. % No. %
1 57 64.8 88 77.2 128 83.1 273 76.7
2 to 4 31 35.2 26 22.8 26 16.9 83 23.3
Total 88 100 114 100 154 100 356 100
P = 0.005; X2 = 10.564; DF = 2.
Table III Distribution of testicular cancer NRH 1970-87:
non-seminoma
1970-75 1976-81 1982-87 Total
Stage No. % No. % No. % No. %
1 44 44.4 60 48.0 90 52.3 194 49.0
2 to 4 55 55.6 65 52.0 82 47.7 202 51.0
Total 99 100 125 100 172 100 396 100
P = 0.442; x2 = 1.633; DF=2.
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culating the incidence of testicular cancer using the Cancer
Registry's figures which show an increase in age adjusted
incidence of approximately 47% from 4.7 per 100,000
annually during the first six-year period to 6.9 per 100,000
annually during the last. The increase in incidence is in
agreement with previous reports both from Norway and
from other countries (Magnus, 1982; Schultz et al., 1984;
Henderson et al., 1988). The reasons for this rise in incidence
are not known.
Discussion
In this material, the increase in number of cases has affected
both seminomas and non-seminomas to the same degree. In
the seminoma patients, almost all of the increase is due to a
doubling of the number of cases in stage 1 while there were
no significant changes in the stage distribution in the non-
seminomas. This finding is in accordance with data from
Denmark (Schultz et al., 1984) who also reported a stage
distribution similar to that in this series. One possible ex-
planation for the improvement in stage distribution in
seminoma would be that it is caused by earlier diagnosis.
Data from the Danish DATECA study (Jacobsen et al.,
1984) indicate that, in Denmark, there has been a gradual
shift towards earlier diagnosis of testicular cancer during the
late part of the 1970s and a small improvement of the stage
distribution during the same period. We believe that there
has also been a reduction in the delay before diagnosis of
testicular cancer in Norway because of an increasing
awareness of the disease both among the general public and
by health professionals. However, there is no general agree-
ment in the literature as to the existence of a positive correla-
tion between the duration of symptoms and stage at present-
ation in testicular carcinoma (Fossa et al., 1981; Bosl et al.,
1981; Jones et al., 1985; Medical Research Council Working
Party, 1985; Chilvers et al., 1989). The present results, with
an increasing percentage of seminomas presenting in stage 1
and decreasing mean age at presentation, could be inter-
preted as supporting the view that there is such a correlation
for this histological subgroup. In the non-seminomas, both
age at presentation and stage distribution remained
unchanged. It may be that these tumours grow and metas-
tasize so rapidly that stage distribution at presentation in
clinical practice is not affected by earlier diagnosis, that is,
they often metastasize before the primary tumour gives rise
to any symptoms.
There have been reports that the increased use of new
technology for staging procedures, especially the use of CT,
induces stage migration in testicular cancer (Feinstein et al.,
1985; Bosl et al., 1988). The stage migration phenomenon
due to the introduction of new technology would usually
alter the apparent stage distribution in the direction of more
cases presenting with advanced disease. In particular, the use
of CT should classify a significant number of former stage 1
patients as stage 4 because of detection of small lung metas-
tases and would, also, detect retroperitoneal metastases not
visible on lymphography. We are aware of the phenomenon
but, based on previous studies from this institution (Lien et
al., 1983a; 1983b; 1988), we believe its effects to be negligible
in the present series. Also, the changes in diagnostic pro-
cedures cannot be responsible for the large increase in stage 1
in the seminomas where CT was introduced as late as 1984.
The increasing incidence and the changing stage distribu-
tion for the seminomas have important implications. Testi-
cular cancer may become a more common disease in young
men in the future. Early testicular cancer is often a curable
disease. Treatment may be associated with serious long-term
morbidity such as infertility. There is growing concern that
some forms of treatment may be associated with the develop-
ment of secondary malignancies. The rising numbers of
patients with testicular cancer, especially of stage 1
seminoma, therefore, calls for an increase of resources for the
development of minimally toxic treatment regimens neces-
sitating long-lasting, frequent, and resource demanding
follow-up at cancer centres.
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